Genomic company ArcherDX Inc said on Tuesday that it has entered into a strategic collaboration to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca's targeted immuno-oncology therapeutics for early-stage non-small cell lung cancer therapies.
Pursuant to the agreement, ArcherDX will perform Whole Exome Sequencing (WES) of resected non-small cell lung cancer (NSCLC) patient samples and generate patient-specific circulating tumour DNA (ctDNA) assays.
In conjunction with the partnership, ArcherDX plans to leverage the PCM assays to develop companion diagnostics (CDx) for AstraZeneca's associated therapies as well as seek global regulatory approval if the Phase 3 clinical trials are completed successfully.
ArcherDX's Personalized Cancer Monitoring (PCM) development programme, which applies its Anchored Multiplex PCR (AMP) technology to accurately detect exceedingly low levels of cancer-derived DNA from patient blood, is supported by Professor Charles Swanton of UCL and the Francis Crick Institute as part of the Cancer Research UK-funded UCL-sponsored TRACERx study.
The master collaboration agreement also allows for expansion into additional disease indications and therapeutic categories.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib